BackCumberland Pharmaceuticals Overview

Cumberland Pharmaceuticals Total Revenue

Track Cumberland Pharmaceuticals's total revenue ($31M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly Revenue

$166458.00
98.46% YoY

As of Jun 2026

Annual Revenue (TTM)

$31.27M
25.68% YoY

Trailing 12 months ending Jun 2026

Average Revenue (Comparison Companies)

Loading

Total Revenue History

Loading

Total Revenue Comparison

Loading

Annual Revenue Growth Rate (%)

Loading

Annual Revenue Growth (Absolute)

Loading

Cumberland Pharmaceuticals (CPIX) FAQ

Cumberland Pharmaceuticals posts a total revenue of $31M as of June 2026. That compares with $42M in the prior-year period — down 25.7% year over year. That is below the Healthcare sector average of $110B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Cumberland Pharmaceuticals's total revenue was $42M. The latest reading is $31M — a 25.7% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a total revenue near $110B is typical. Cumberland Pharmaceuticals's $31M is lower that level. That is roughly 100.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Total Revenue is one piece of Cumberland Pharmaceuticals's financial statement story. At $31M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for CPIX's total revenue usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $110B), and (3) consistency with growth and profitability. This page covers the first two; Cumberland Pharmaceuticals's other metric pages and overview cover the third.